

Magdalena M Martusewicz-Boros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5759091/publications.pdf>

Version: 2024-02-01

25
papers

257
citations

1163117

8
h-index

940533

16
g-index

28
all docs

28
docs citations

28
times ranked

455
citing authors

#	ARTICLE	IF	CITATIONS
1	Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?. Journal of Clinical Oncology, 2008, 26, 5134-5136.	1.6	61
2	Pulmonary Intravascular Large B-Cell Lymphoma As a Cause of Severe Hypoxemia. Journal of Clinical Oncology, 2007, 25, 2137-2139.	1.6	34
3	Cardiac Sarcoidosis: Is it More Common in Men?. Lung, 2016, 194, 61-66.	3.3	32
4	Prevalence of cardiac sarcoidosis in white population. Medicine (United States), 2016, 95, e4518.	1.0	30
5	What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 115-20.	0.2	28
6	Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Advances in Respiratory Medicine, 2020, 88, 42-94.	1.0	19
7	Intratracheal Dilation-injection Technique in the Treatment of Granulomatosis with Polyangiitis Patients with Subglottic Stenosis. Journal of Rheumatology, 2016, 43, 2042-2048.	2.0	9
8	A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC Pulmonary Medicine, 2020, 20, 122.	2.0	9
9	Pulmonary Function Abnormalities in Regard to Age at the Time of Diagnosis of Hypersensitivity Pneumonitis. Advances in Experimental Medicine and Biology, 2015, 861, 75-84.	1.6	5
10	Systemic treatment for sarcoidosis was needed for 16% of 1810 Caucasian patients. Clinical Respiratory Journal, 2018, 12, 1367-1371.	1.6	5
11	Reversibility of Airway Obstruction vs Bronchodilatation: Do We Speak the Same Language?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 213-215.	1.6	4
12	Respiratory system involvement in chronic liver diseases. Polish Archives of Internal Medicine, 2013, 123, 635-642.	0.4	4
13	Idiopathic pulmonary fibrosis (IPF) – common practice in Poland before the –antifibrotic drugs era–. Advances in Respiratory Medicine, 2017, 85, 136-142.	1.0	4
14	Diagnosis of Sarcoidosis–The Updated ATS 2020 Recommendations through the Prism of Everyday Clinical Practice. Advances in Respiratory Medicine, 2020, 88, 293-296.	1.0	3
15	Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry. , 2017, , .		2
16	Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey. Advances in Respiratory Medicine, 2020, 87, 221-230.	1.0	2
17	Cardiac sarcoidosis: worse pulmonary function due to left ventricular ejection fraction?. Medicine (United States), 2019, 98, e18037.	1.0	1
18	Cardiac sarcoidosis: worse pulmonary function due to left ventricular ejection fraction ? A case-control study. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
19	A case report of steroid resistant cardiac sarcoidosis successfully managed with methotrexate. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 178-181.	0.2	1
20	Cardiac Sarcoidosis Treatment Revisited. Internal Medicine, 2014, 53, 2759-2759.	0.7	0
21	Risk factors for cardiac involvement in sarcoidosis - A case-control study in 201 Caucasian patients. , 2016, , .		0
22	Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry. , 2017, , .		0
23	Gender and smoking “ does it matter for lung function in sarcoidosis? An analysis of large cohort (n=1260) Caucasian patients.. , 2018, , .		0
24	Progressive fibrosis in interstitial lung diseases “ proposed definition and management. Advances in Respiratory Medicine, 2021, 89, 505-510.	1.0	0
25	Cardiac sarcoidosis - silent destroyer. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2016, 33, 175-7.	0.2	0